Protagenic Therapeutics Ownership 2024 | Who Owns Protagenic Therapeutics Now?
Institutional Ownership
14.16%
Insider Ownership
21.67%
Retail Ownership
64.17%
Institutional Holders
15.00
Protagenic Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 0.03% | - | 32,951 | 32,951 | 100.00% | 57,005,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.03% | - | 25,399 | 25,399 | 100.00% | 43,940,000 | Mar 31, 2023 |
FNY INVESTMENT ADVISERS, LLC | 0.02% | 0.04% | 18,750 | 18,750 | 100.00% | 32,000 | Mar 31, 2023 |
STATE STREET CORP | 0.01% | - | 13,812 | 13,812 | 100.00% | 23,895,000 | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 2,764 | 2,764 | 100.00% | 4,781,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,438 | 1,438 | 100.00% | 2,000 | Mar 31, 2023 |
UBS GROUP AG | 0.00% | - | 305 | 305 | 100.00% | 528,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | 23 | 23 | 100.00% | 40,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
MORGAN STANLEY | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,552 | -100.00% | - | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -25,899 | -100.00% | - | Mar 31, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -5,000 | -100.00% | - | Mar 31, 2023 |
VANGUARD GROUP INC | - | - | - | -59,078 | -100.00% | - | Mar 31, 2023 |
CONCORDE ASSET MANAGEMENT, LLC | - | - | - | -4,180 | -100.00% | - | Mar 31, 2023 |
FNY INVESTMENT ADVISERS, LLC | - | - | - | -18,750 | -100.00% | - | Mar 31, 2023 |
CITADEL ADVISORS LLC | - | - | - | -5,871 | -100.00% | - | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -4,289 | -100.00% | - | Mar 31, 2023 |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -3,495 | -100.00% | - | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -2,764 | -100.00% | - | Mar 31, 2023 |
Protagenic Therapeutics's largest institutional shareholder is VANGUARD GROUP INC, holding 0.03% of the company's total share outstanding, currently valued at $57.01M. The top 10 institutional shareholders own together 0.10% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
FNY INVESTMENT ADVISERS, LLC | 0.02% | 0.04% | 18,750 | 18,750 | 100.00% | 32,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,438 | 1,438 | 100.00% | 2,000 | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 2,764 | 2,764 | 100.00% | 4,781,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.03% | - | 25,399 | 25,399 | 100.00% | 43,940,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.03% | - | 32,951 | 32,951 | 100.00% | 57,005,000 | Mar 31, 2023 |
STATE STREET CORP | 0.01% | - | 13,812 | 13,812 | 100.00% | 23,895,000 | Mar 31, 2023 |
UBS GROUP AG | 0.00% | - | 305 | 305 | 100.00% | 528,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | 23 | 23 | 100.00% | 40,000 | Mar 31, 2023 |
MORGAN STANLEY | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,552 | -100.00% | - | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -25,899 | -100.00% | - | Mar 31, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -5,000 | -100.00% | - | Mar 31, 2023 |
VANGUARD GROUP INC | - | - | - | -59,078 | -100.00% | - | Mar 31, 2023 |
CONCORDE ASSET MANAGEMENT, LLC | - | - | - | -4,180 | -100.00% | - | Mar 31, 2023 |
FNY INVESTMENT ADVISERS, LLC | - | - | - | -18,750 | -100.00% | - | Mar 31, 2023 |
CITADEL ADVISORS LLC | - | - | - | -5,871 | -100.00% | - | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -4,289 | -100.00% | - | Mar 31, 2023 |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -3,495 | -100.00% | - | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -2,764 | -100.00% | - | Mar 31, 2023 |
The largest Protagenic Therapeutics shareholder by % of total assets is FNY INVESTMENT ADVISERS, LLC. The company owns 18.75K shares of Protagenic Therapeutics (PTIX), representing 0.04% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 0.03% | - | 32,951 | 32,951 | 100.00% | 57,005,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.03% | - | 25,399 | 25,399 | 100.00% | 43,940,000 | Mar 31, 2023 |
FNY INVESTMENT ADVISERS, LLC | 0.02% | 0.04% | 18,750 | 18,750 | 100.00% | 32,000 | Mar 31, 2023 |
STATE STREET CORP | 0.01% | - | 13,812 | 13,812 | 100.00% | 23,895,000 | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 2,764 | 2,764 | 100.00% | 4,781,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,438 | 1,438 | 100.00% | 2,000 | Mar 31, 2023 |
UBS GROUP AG | 0.00% | - | 305 | 305 | 100.00% | 528,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | 23 | 23 | 100.00% | 40,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
MORGAN STANLEY | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | - | -1 | -100.00% | - | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -23 | -100.00% | - | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,552 | -100.00% | - | Mar 31, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -2,528 | -100.00% | - | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -2,764 | -100.00% | - | Mar 31, 2023 |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -3,495 | -100.00% | - | Mar 31, 2023 |
CONCORDE ASSET MANAGEMENT, LLC | - | - | - | -4,180 | -100.00% | - | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -4,289 | -100.00% | - | Mar 31, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -5,000 | -100.00% | - | Mar 31, 2023 |
NORTHERN TRUST CORP | - | - | - | -5,622 | -100.00% | - | Mar 31, 2023 |
As of Mar 31 2023, Protagenic Therapeutics's largest institutional buyer is VANGUARD GROUP INC. The company purchased 32.95K stocks of PTIX, valued at $57.01M.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | - | - | - | -59,078 | -100.00% | - | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -25,899 | -100.00% | - | Mar 31, 2023 |
FNY INVESTMENT ADVISERS, LLC | - | - | - | -18,750 | -100.00% | - | Mar 31, 2023 |
STATE STREET CORP | - | - | - | -13,812 | -100.00% | - | Mar 31, 2023 |
CITADEL ADVISORS LLC | - | - | - | -5,871 | -100.00% | - | Mar 31, 2023 |
NORTHERN TRUST CORP | - | - | - | -5,622 | -100.00% | - | Mar 31, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -5,000 | -100.00% | - | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -4,289 | -100.00% | - | Mar 31, 2023 |
CONCORDE ASSET MANAGEMENT, LLC | - | - | - | -4,180 | -100.00% | - | Mar 31, 2023 |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -3,495 | -100.00% | - | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -2,764 | -100.00% | - | Mar 31, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -2,528 | -100.00% | - | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,552 | -100.00% | - | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -23 | -100.00% | - | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | - | -1 | -100.00% | - | Mar 31, 2023 |
MORGAN STANLEY | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | 23 | 23 | 100.00% | 40,000 | Mar 31, 2023 |
UBS GROUP AG | 0.00% | - | 305 | 305 | 100.00% | 528,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,438 | 1,438 | 100.00% | 2,000 | Mar 31, 2023 |
As of Mar 31 2023, Protagenic Therapeutics's biggest institutional seller is VANGUARD GROUP INC. The company sold -59.08K shares of PTIX, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 0.03% | - | 32,951 | 32,951 | 100.00% | 57,005,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.03% | - | 25,399 | 25,399 | 100.00% | 43,940,000 | Mar 31, 2023 |
FNY INVESTMENT ADVISERS, LLC | 0.02% | 0.04% | 18,750 | 18,750 | 100.00% | 32,000 | Mar 31, 2023 |
STATE STREET CORP | 0.01% | - | 13,812 | 13,812 | 100.00% | 23,895,000 | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 2,764 | 2,764 | 100.00% | 4,781,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,438 | 1,438 | 100.00% | 2,000 | Mar 31, 2023 |
UBS GROUP AG | 0.00% | - | 305 | 305 | 100.00% | 528,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | 23 | 23 | 100.00% | 40,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
MORGAN STANLEY | - | - | 1 | 1 | 100.00% | 2,000 | Mar 31, 2023 |
Protagenic Therapeutics's largest new institutional shareholder by number of shares is VANGUARD GROUP INC, purchased 32.95K shares, valued at $57.01M, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | - | - | - | -59,078 | -100.00% | - | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -25,899 | -100.00% | - | Mar 31, 2023 |
FNY INVESTMENT ADVISERS, LLC | - | - | - | -18,750 | -100.00% | - | Mar 31, 2023 |
STATE STREET CORP | - | - | - | -13,812 | -100.00% | - | Mar 31, 2023 |
CITADEL ADVISORS LLC | - | - | - | -5,871 | -100.00% | - | Mar 31, 2023 |
NORTHERN TRUST CORP | - | - | - | -5,622 | -100.00% | - | Mar 31, 2023 |
WARBERG ASSET MANAGEMENT LLC | - | - | - | -5,000 | -100.00% | - | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -4,289 | -100.00% | - | Mar 31, 2023 |
CONCORDE ASSET MANAGEMENT, LLC | - | - | - | -4,180 | -100.00% | - | Mar 31, 2023 |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -3,495 | -100.00% | - | Mar 31, 2023 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -2,764 | -100.00% | - | Mar 31, 2023 |
VIRTU FINANCIAL LLC | - | - | - | -2,528 | -100.00% | - | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,552 | -100.00% | - | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | - | - | - | -23 | -100.00% | - | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | - | -1 | -100.00% | - | Mar 31, 2023 |
Protagenic Therapeutics's largest sold out institutional shareholder by shares sold is VANGUARD GROUP INC, sold -59.08K shares, valued at -, as of undefined.
Protagenic Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
VANGUARD INDEX FUNDS | 0.00% | 242,731 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 101,596 | - | - | Feb 29, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 25,123 | - | - | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 31,996 | -31,996 | -50.00% | Mar 31, 2024 |
Protagenic Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 242.73K shares, compromising 0.00% of its total assets.
Protagenic Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Dec, 22 | 15 | 25.00% |
30 Sep, 22 | 12 | 9.09% |
30 Jun, 22 | 11 | -8.33% |
31 Mar, 22 | 12 | -7.69% |
31 Dec, 21 | 13 | 8.33% |
30 Sep, 21 | 12 | 100.00% |
30 Jun, 21 | 6 | - |
As of 31 Dec 22, 15 institutions are holding Protagenic Therapeutics's shares, representing an increase of 25.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Dec, 22 | 611,430 | 2.25% |
30 Sep, 22 | 597,947 | -1.11% |
30 Jun, 22 | 604,644 | -10.29% |
31 Mar, 22 | 673,973 | -29.32% |
31 Dec, 21 | 953,552 | -0.13% |
30 Sep, 21 | 954,781 | 326.47% |
30 Jun, 21 | 223,881 | - |
Protagenic Therapeutics (PTIX) has 611.43K shares outstanding as of 31 Dec 22, up 2.25% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Dec, 22 | 14.16% | 7.40% |
30 Sep, 22 | 13.84% | 7.06% |
30 Jun, 22 | 14.00% | 5.72% |
31 Mar, 22 | 15.64% | 2.34% |
31 Dec, 21 | 25.88% | 4.84% |
30 Sep, 21 | 23.12% | 60.50% |
30 Jun, 21 | 6.18% | - |
As of 31 Dec 22, Protagenic Therapeutics is held by 14.16% institutional shareholders, representing a 7.40% growth compared to 30 Sep 22.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Dec, 22 | 6 | 20.00% |
30 Sep, 22 | 5 | 25.00% |
30 Jun, 22 | 4 | -20.00% |
31 Mar, 22 | 5 | -28.57% |
31 Dec, 21 | 7 | -30.00% |
30 Sep, 21 | 10 | 66.67% |
30 Jun, 21 | 6 | - |
6 institutional shareholders have increased their position in PTIX stock as of 31 Dec 22 compared to 5 in the previous quarter (a 20.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Dec, 22 | 4 | 300.00% |
30 Sep, 22 | 1 | -50.00% |
30 Jun, 22 | 2 | -33.33% |
31 Mar, 22 | 3 | 50.00% |
31 Dec, 21 | 2 | 100.00% |
30 Sep, 21 | 1 | - |
30 Jun, 21 | - | - |
4 institutional shareholders have reduced their position in PTIX stock as of 31 Dec 22 compared to 1 in the previous quarter (a 300.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Dec, 22 | 15 | 25.00% | 611,430 | 2.25% | 14.16% | 7.40% | 6 | 20.00% | 4 | 300.00% |
30 Sep, 22 | 12 | 9.09% | 597,947 | -1.11% | 13.84% | 7.06% | 5 | 25.00% | 1 | -50.00% |
30 Jun, 22 | 11 | -8.33% | 604,644 | -10.29% | 14.00% | 5.72% | 4 | -20.00% | 2 | -33.33% |
31 Mar, 22 | 12 | -7.69% | 673,973 | -29.32% | 15.64% | 2.34% | 5 | -28.57% | 3 | 50.00% |
31 Dec, 21 | 13 | 8.33% | 953,552 | -0.13% | 25.88% | 4.84% | 7 | -30.00% | 2 | 100.00% |
30 Sep, 21 | 12 | 100.00% | 954,781 | 326.47% | 23.12% | 60.50% | 10 | 66.67% | 1 | - |
30 Jun, 21 | 6 | - | 223,881 | - | 6.18% | - | 6 | - | - | - |
Protagenic Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Protagenic Therapeutics's stock was made by Barrage Khalil on May 05 2021, selling 45,000 shares at $1.25 per share (valued at $56.25K). The last insider buy of PTIX was made by Arrow Alexander K. on Oct 13 2023, buying 8,000 shares at $0.81 per share (worth $6.48K).
Protagenic Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q4 2023 | 1 | - | - |
Q2 2022 | 1 | - | - |
Q4 2006 | - | 1 | - |
1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Protagenic Therapeutics's insiders, as of Q4 2023.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q4 2023 | 1 | - | - |
Q2 2022 | 1 | - | - |
Q4 2006 | - | 1 | - |
As of Q4 2023, Insider owners conducted 1 open market buy trades and 0 open market sell trades of Protagenic Therapeutics's stocks.
PTIX Ownership FAQ
Who Owns Protagenic Therapeutics?
Protagenic Therapeutics is owned by institutional shareholders (14.16%), insiders (21.67%), and public (64.17%). The largest institutional shareholder of Protagenic Therapeutics is VANGUARD GROUP INC (0.03% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).
Who are the major institutional shareholders of Protagenic Therapeutics?
Protagenic Therapeutics's major institutional shareholders are VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, FNY INVESTMENT ADVISERS, LLC, STATE STREET CORP, and ADVISOR GROUP HOLDINGS, INC.. The top five shareholders own together 0.09% of the company's share outstanding.
How many Protagenic Therapeutics shareholders are there?
As of Dec 2022, there are 15 institutional shareholders of Protagenic Therapeutics.
What percentage of Protagenic Therapeutics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC owns 32.95K shares of Protagenic Therapeutics, representing 0.03% of the company's total shares outstanding, valued at $57M (as of Mar 2023).
What percentage of Protagenic Therapeutics is owned by GEODE CAPITAL MANAGEMENT, LLC?
As of Mar 2023, GEODE CAPITAL MANAGEMENT, LLC holds 25.4K shares of Protagenic Therapeutics (PTIX), compromising 0.03% of the company, valued at $43.94M.
What percentage of Protagenic Therapeutics is owned by FNY INVESTMENT ADVISERS, LLC?
FNY INVESTMENT ADVISERS, LLC is the third largest holder of Protagenic Therapeutics. The company owns 18.75K of the company's shares outstanding (worth $32K).